A股異動丨瑞康醫藥漲停 阿比朵爾在售且與達蘆那韋生產企業有合作
格隆匯2月6日丨瑞康醫藥(002589.SZ)漲停,報8.49元,總市值127.75億元。瑞康醫藥在互動平台稱,公司關注到李蘭娟院士發佈的研究成果,目前,公司有阿比朵爾在售,且庫存充足;與達蘆那韋生產企業有着長期合作關係,購銷渠道通暢,可隨時響應醫療機構的使用需求。瑞康醫藥還表示,目前公司在湖北省和武漢市共有4家子公司,各公司經營情況正常。截至2月4日,子公司武漢倍安經貿有限公司又為武漢火神山醫院裝配10台CRRT,為武漢雷神山醫院裝配16台呼吸機,為黃石市中醫醫院緊急安裝了8台呼吸機。目前,武漢倍安還在與武漢市衞健委溝通,爭取進入“方艙醫院”設備供應名單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.